$1.21
0.05[4.31%]
At close: May 13
$1.21
0[0.00%]
After Hours: 4:18PM EDT
FibroGen
(NASDAQ:FGEN)Latest News for FibroGen Stock (NASDAQ:FGEN)
FibroGen Stock (NASDAQ: FGEN)
Categories: All
Tuesday, May 07, 2024
- Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - 6 days ago
- FibroGen Shares Climb On Strong Q1 SalesErica Kollmann - 6 days ago
- Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On TuesdayAvi Kapoor - 6 days ago
- Why Zeta Global Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving PremarketAvi Kapoor - 6 days ago
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - 6 days ago
- FibroGen shares are trading higher after the company reported mixed Q1 financial results.Benzinga Newsdesk - 6 days ago
Monday, May 06, 2024
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga Insights - May 6, 2024, 4:31PM
- FibroGen shares are trading higher after the company reported mixed Q1 financial results.Benzinga Newsdesk - May 6, 2024, 4:29PM
- FibroGen Q1 2024 GAAP EPS $(0.33) Misses $(0.31) Estimate, Sales $55.902M Beat $36.666M EstimateBenzinga Newsdesk - May 6, 2024, 4:19PM
Wednesday, April 24, 2024
Wednesday, April 03, 2024
- FibroGen shares are trading lower after the company announced topline results from the Phase 1 monotherapy study of FG-3246 in patients with metastatic castration-resistant prostate cancer.Benzinga Newsdesk - Apr 3, 2024, 2:43PM
- Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Apr 3, 2024, 1:56PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Apr 3, 2024, 12:31PM
- FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The LandscapeVandana Singh - Apr 3, 2024, 10:02AM
Tuesday, April 02, 2024
Tuesday, March 12, 2024
Monday, February 26, 2024
- Recap: FibroGen Q4 EarningsBenzinga Insights - Feb 26, 2024, 4:25PM
- FibroGen Q4 2023 GAAP EPS $(0.57) Misses $(0.42) Estimate, Sales $27.14M Miss $38.90M EstimateBenzinga Newsdesk - Feb 26, 2024, 4:20PM
- FibroGen And AstraZeneca Agree To Terminate Roxadustat Collaboration Agreement Entered On Jul. 30, 2013; FibroGen Regains All Rights To Roxadusta In United States And Other AstraZeneca Territories, Except China And South KoreaBenzinga Newsdesk - Feb 26, 2024, 4:06PM
- Earnings Scheduled For February 26, 2024Benzinga Insights - Feb 26, 2024, 4:47AM
Friday, February 23, 2024
Wednesday, February 07, 2024
Friday, February 02, 2024
Monday, January 29, 2024
Thursday, January 25, 2024
Sunday, December 10, 2023
Tuesday, November 07, 2023
Monday, November 06, 2023
Wednesday, October 04, 2023
Tuesday, September 19, 2023
Friday, September 15, 2023
Thursday, September 07, 2023
Wednesday, August 30, 2023
- FibroGen shares are trading lower after the company's Phase 3 Trial of Pamrevlumab did not meet its primary endpoint.Bill Haddad - Aug 30, 2023, 3:56PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Aug 30, 2023, 1:31PM
- Why REX American Resources Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionLisa Levin - Aug 30, 2023, 1:17PM
- Gold Moves Higher; Outlook Therapeutics Shares PlummetLisa Levin - Aug 30, 2023, 12:28PM
- Dow Surges 150 Points; US Economy Grows At 2.1% Pace In Q2Lisa Levin - Aug 30, 2023, 10:04AM
- Why NanoVibronix Shares Are Trading Higher By 49%; Here Are 20 Stocks Moving PremarketLisa Levin - Aug 30, 2023, 9:14AM
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga Insights - Aug 30, 2023, 9:06AM
- Three In A Row: FibroGen's Investigational Drug Flunks In Another Study For Rare Disease In Young BoysVandana Singh - Aug 30, 2023, 7:42AM
Tuesday, August 29, 2023
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga Insights - Aug 29, 2023, 5:31PM
- FibroGen Announces Topline Results From LELANTOS-2, A Phase 3 Clinical Study of Pamrevlumab In Ambulatory Duchenne Muscular Dystrophy; Study Did Not Meet The Primary EndpointBenzinga Newsdesk - Aug 29, 2023, 4:19PM
Wednesday, August 09, 2023
Tuesday, August 08, 2023
- Stocks That Hit 52-Week Lows On TuesdayBenzinga Insights - Aug 8, 2023, 1:32PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Aug 8, 2023, 1:31PM
- Expert Ratings for FibroGenBenzinga Insights - Aug 8, 2023, 11:00AM
- Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023Benzinga Insights - Aug 8, 2023, 11:00AM
- B of A Securities Downgrades FibroGen to Underperform, Lowers Price Target to $2Benzinga Newsdesk - Aug 8, 2023, 8:49AM